Iovance Biotherapeutics has been granted a patent for a method to treat melanoma by re-stimulating tumor infiltrating lymphocytes (TILs) for improved efficacy. The method involves multiple expansions of TIL populations in cell culture medium with specific supplements before administering to the subject. GlobalData’s report on Iovance Biotherapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Iovance Biotherapeutics, Cytokine activate T-cell based compositions was a key innovation area identified from patents. Iovance Biotherapeutics's grant share as of April 2024 was 17%. Grant share is based on the ratio of number of grants to total number of patents.
Method for treating melanoma with re-stimulated til populations
A recently granted patent (Publication Number: US11969444B2) outlines a method for treating melanoma by administering expanded tumor infiltrating lymphocytes (TILs) to a subject. The process involves multiple steps, including thawing cryopreserved dissociated tumor materials, culturing the TILs in a cell culture medium with IL-2, supplementing with additional IL-2, OKT-3, and antigen presenting cells (APCs) for expansion, harvesting the TILs, cryopreserving them, and finally administering a therapeutically effective dosage to the subject. The expansion process is crucial, lasting about 14 to 22 days to obtain the therapeutic TIL population.
Furthermore, the patent includes additional details such as the use of tumor digests or fragments for obtaining dissociated tumor materials, the inclusion of a non-myeloablative lymphodepletion regimen before TIL administration, and the option for a high-dose IL-2 regimen post-TIL treatment. The method also emphasizes closed system handling to prevent contamination and specifies timeframes for each step, ensuring efficiency in the production of TILs. Cryopreservation of dissociated tumor materials using a cryopreservation media with DMSO is highlighted, with a specific concentration of 5% DMSO mentioned for optimal preservation. These detailed claims provide a comprehensive guide for utilizing TILs in melanoma treatment, potentially offering a promising therapeutic approach for patients with this type of cancer.
To know more about GlobalData’s detailed insights on Iovance Biotherapeutics, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
